Type of publication:
Conference abstract
Author(s):
*Lake B.; *Wilson M.; *Appleton D.
Citation:
Annals of Surgical Oncology. Conference: 25th American Society of Breast Surgeons Annual Meeting, ASBrS 2024. Orlando, FL United States. 31(Supplement 2) (pp S498), 2024. Date of Publication: 01 Jun 2024.
Abstract:
Background/Objective: Magtrace is an iron oxide liquid which has revolutionized sentinel lymph node biopsy treatment for breast cancer. It has a flexible injection window which allows patients to have the injection prior to the day of surgery at a convenient time for both the patient and the provider and removes the need for nuclear medicine completely. Magtrace was reviewed by the National Institute for Health and Care Excellence in October 2022 (MTG72) and they highlighted that Magtrace has the potential to reduce cost based on an expectation that its usage would enable hospitals to perform additional sentinel node biopsies due to improved operating room utilization. The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care in the UK. This guidance is the gold standard for advice for breast cancer treatment. Our team designed a study to investigate the "additive effect" of Magtrace in improving theatre efficiency, operative capacity, and patient experience (Presented at European Society of Surgical Oncology, to be published in European Journal of Surgical Oncology early 2025). The aim of this study was to assess if these previously described benefits of Magtrace by NICE are sustained in a hospital system. Method(s): All Magtrace cases for sentinel node biopsy at the Shrewsbury & Telford NHS Trust were prospectively recorded. The outcomes measured were operating room utilization, number of sentinel node biopsies performed per week, and patient satisfaction. Result(s): 150 patients undergoing a wide local excision or mastectomy received Magtrace as the sole technique for SLNB. Operating room utilization improved from 77% to 84% (with peak utilisation at 96%) due to a reduction in OR delays and improved OR flow. Previous delays were caused by patients waiting to have radioisotope injections. Significantly more sentinel node biopsies were performed per week, increasing from 6.48 per week (Pre Magtrace 2022) to 8.57 per week (Post Magtrace ) (t-value = 3.53057, p-value < 0.00041). This resulted in a net increase of 2 additional patients per week. The t-value is 3.53057. The p-value is .00041. The result is significant at p < 0.05. The study showed high patient satisfaction with 100% of patients finding injection more convenient on the day of surgery and 100% of patients would recommend Magtrace to a friend or relative. Conclusion(s): Utilising Magtrace for sentinel lymph node biopsy creates a sustained "additive effect" by improving operating room utilization, operating room capacity and demonstrates a high patient satisfaction.
DOI: 10.1245/s10434-024-15410-w
Link to full-text [NHS OpenAthens account required]
